Cambium Bio Limited
CMB
Rank in Stocks
#32553
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on... Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Share Price
$0.31737816
Market Cap
$9.34M
Change (1 day)
0.00%
Change (1 year)
5,917.33%
Country
AU
Trade Cambium Bio Limited (CMB)
Category
Healthcare
Earnings for Cambium Bio Limited (CMB)
Earnings in 2026 TTM: 0
According to Cambium Bio Limited latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Cambium Bio Limited from 2026 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| - | - |
CH
|
|
| $1.95B | - |
NL
|
